Literature DB >> 17674765

[Expression and significance of tyrosine kinase receptors B in nasopharyngeal carcinoma patients].

Weimin Zhao1, Wensheng Wen, Zhe Zhang, Zhiling Liao, Shuxiang Zhang, Guangwu Huang.   

Abstract

OBJECTIVE: This study was to explore the expression and clinicopathologic features of Tyrosine kinase receptors B (TrkB) and its ligand brain-derived neurotrophic factor (BDNF) in nasopharyngeal carcinoma (NPC).
METHOD: Immunohistochemistry was adopted to detect the expression level of TrkB and BDNF in NPC patients. RESULT: Both TrkB and BDNF were expressed in NPC as well as in chronic inflammation. The active expression rate of TrkB in NPC was 82.5% (47/57) and BDNF was 52.6% (30/57), both of which were higher than those in chronic inflammation (P < 0.05). The degree of TrkB expression was more marked in T3 + T4, III + IV stage NPC than that in T1 +T2, I + II stage NPC (P < 0.05). TrkB abnormal expression rate of nasopharyngeal carcinoma with lymph node metastasis was higher than that of NPC without lymph node metastasis (P < 0.05). No statistical significance for degrees of TrkB expression in pathologic type grades was found (P > 0.05). There were no statistical significance for degrees of BDNF expression in T stage, clinical stage and lymph node metastasis in NPC (P > 0.05). The expression of TrkB was unrelated to the expression of BDNF (r = 0.049, P > 0.05).
CONCLUSION: The high expression rate of TrkB and BDNF maybe plays an important role in development of NPC. It is suggested that TrkB and its ligand BDNF may act as an important index for forecasting the development and metastasis of NPC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674765

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 2096-7993


  2 in total

1.  K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells.

Authors:  Yuen-Keng Ng; Elaine Yue Ling Wong; Cecilia Pik Yuk Lau; Jessica Pui Lan Chan; Sze Chuen Cesar Wong; Andrew Sai-Kit Chan; Maggie Pui Chun Kwan; Sai-Wah Tsao; Chi-Man Tsang; Paul Bo San Lai; Anthony Tak Cheung Chan; Vivian Wai Yan Lui
Journal:  Invest New Drugs       Date:  2010-08-07       Impact factor: 3.850

Review 2.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.